• Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=1568228).
  

PubMed=2323006; DOI=10.1093/carcin/11.4.673
Pelin-Enlund K., Husgafvel-Pursiainen K., Tammilehto L., Klockars M., Jantunen K., Gerwin B.I., Harris C.C., Tuomi T., Vanhala E., Mattson K., Linnainmaa K.
Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients.
Carcinogenesis 11:673-681(1990)

PubMed=1568228
Metcalf R.A., Welsh J.A., Bennett W.P., Seddon M.B., Lehman T.A., Pelin-Enlund K., Linnainmaa K., Tammilehto L., Mattson K., Gerwin B.I., Harris C.C.
p53 and Kirsten-ras mutations in human mesothelioma cell lines.
Cancer Res. 52:2610-2615(1992)

CLPUB00243
Kahlos K.
The expression and possible role of manganese superoxide dismutase in malignant pleural mesothelioma.
Thesis PhD (1999), University of Oulu, Finland

PubMed=11283936; DOI=10.1002/1097-0142(20010401)91:7<1349::AID-CNCR1138>3.0.CO;2-D
Kahlos K., Soini Y., Sormunen R., Kaarteenaho-Wiik R., Paakko P., Linnainmaa K., Kinnula V.L.
Expression and prognostic significance of catalase in malignant mesothelioma.
Cancer 91:1349-1357(2001)